secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2022-04-05T23:59:59+00:00
Accession:  0001193125-22-096290
Event type: other_material
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 1.02, 3.02, 5.03, 3.03, 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fluidigm closes $225M convertible preferred financing, renames to Standard BioTools, appoints new CEO and board
--------------------------------------------------------------------------------

- Closed $225M private placement of Series B convertible preferred to Casdin and Viking (112,500 shares each at $1,000/share).
- Name changed from Fluidigm to Standard BioTools; authorized common shares doubled to 400M.
- Appointed Michael Egholm as CEO/President and Hanjoon Alex Kim as COO; former CEO Linthwaite resigned.
- Board expanded to 8; new directors: Eli Casdin, Martin Madaus, Frank Witney, and Michael Egholm.
- Adopted 2022 Inducement Plan reserving 9.5M shares; granted Egholm options for 4.5M shares and Kim 1.6M shares at $3.99.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000119312522096290/0001193125-22-096290-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000119312522096290/d314141d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-096290

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer